RemeGen Co (HKSE:09995) Equity-to-Asset : 0.62 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. RemeGen Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$3,759.6 Mil. RemeGen Co's Total Assets for the quarter that ended in Dec. 2023 was HK$6,046.7 Mil.

The historical rank and industry rank for RemeGen Co's Equity-to-Asset or its related term are showing as below:

HKSE:09995' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.94 Med: 0.72 Max: 0.87
Current: 0.62

During the past 6 years, the highest Equity to Asset Ratio of RemeGen Co was 0.87. The lowest was -0.94. And the median was 0.72.

HKSE:09995's Equity-to-Asset is ranked worse than
53.86% of 1567 companies
in the Biotechnology industry
Industry Median: 0.66 vs HKSE:09995: 0.62

RemeGen Co Equity-to-Asset Historical Data

The historical data trend for RemeGen Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Equity-to-Asset Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

Get a 7-Day Free Trial

-0.34

0.87

0.83

0.62

RemeGen Co Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Equity-to-Asset	Get a 7-Day Free Trial									0.83	0.74	-	0.62	-

Competitive Comparison of RemeGen Co's Equity-to-Asset

For the Biotechnology subindustry, RemeGen Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RemeGen Co's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Equity-to-Asset falls into.

RemeGen Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

RemeGen Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	3759.612	/	6046.675
	=	0.62

RemeGen Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	3759.612	/	6046.675
	=

RemeGen Co (HKSE:09995) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

RemeGen Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co (HKSE:09995) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

REGMF:USA REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

http://www.remegen.com

RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

RemeGen Co (HKSE:09995) Headlines

No Headlines